The FMR1 gene, infertility, and reproductive decision-making: A review

Frontiers in Genetics

Volumn 5, Issue JUL, 2014, Pages

  Pastore, Lisa M ^a   Johnson, Joshua ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti mullerian hormone; Diminished ovarian reserve; Female infertility; FMR1; Follicle stimulating hormone; Genetic counseling; Mouse models; Primary ovarian insufficiency

Indexed keywords

ESTRADIOL; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

AUTISM; CELL SURVIVAL; CLINICAL DECISION MAKING; FEMALE INFERTILITY; FRAGILE X MENTAL RETARDATION GENE; FRAGILE X SYNDROME; GENE; GENE EXPRESSION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; NONHUMAN; OVARIAN RESERVE; PLURIPOTENT STEM CELL; PREMATURE OVARIAN FAILURE; REVIEW; TRINUCLEOTIDE REPEAT;

EID: 84906247986     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00195     Document Type: Review

References (77)

1. ACOG Committee of Genetics. (2010). Carrier Screening for Fragile X Syndrome. Obstet. Gynecol. 116, 1008-1010. doi: 10.1097/AOG.0b013e3181fae884
2. Anido, A., Carlson, L. M., and Sherman, S. L. (2007). Attitudes toward fragile X mutation carrier testing from women identified in a general population survey. J. Genet. Couns. 16, 97-104. doi: 10.1007/s10897-006-9049-0
3. Anido, A., Carlson, L. M., Taft, L., and Sherman, S. (2005). Women's attitudes toward testing for fragile X carrier status: a qualitative analysis. J. Genet. Couns. 14, 295-306. doi: 10.1007/s10897-005-1159-6
4. Ashley-Koch, A. E., Robinson, H., Glicksman, A. E., Nolin, S. L., Schwartz, C. E., Brown, W. T., et al. (1998). Examination of factors associated with instability of the FMR1 CGG repeat. Am. J. Hum. Genet. 63, 776-785. doi: 10.1086/302018
5. Barasoain, M., Barrenetxea, G., Huerta, I., Telez, M., Carrillo, A., Perez, C., et al. (2013). Study of FMR1 gene association with ovarian dysfunction in a sample from the Basque Country. Gene 521, 145-149. doi: 10.1016/j.gene.2013.03.032
6. Bloss, C. S., Darst, B. F., Topol, E. J., and Schork, N. J. (2011). Direct-to-consumer personalized genomic testing. Hum. Mol. Genet. 20, R132-R141. doi: 10.1093/hmg/ddr349
7. Bodega, B., Bione, S., Dalpra, L., Toniolo, D., Ornaghi, F., Vegetti, W., et al. (2006). Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum. Reprod. 21, 952-957. doi: 10.1093/humrep/dei432
8. Bretherick, K. L., Fluker, M. R., and Robinson, W. P. (2005). FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum. Genet. 117, 376-382. doi: 10.1007/s00439-005-1326-8
9. Brown, W. T., Houck, G. E. Jr., Ding, X., Zhong, N., Nolin, S., Glicksman, A., et al. (1996). Reverse mutations in the fragile X syndrome. Am. J. Med. Genet. 64, 287-292.
10. Burger, H. G. (1994). Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition-an analysis of FSH, oestradiol and inhibin. Eur. J. Endocrinol. 130, 38-42. doi: 10.1530/eje.0.1300038
11. Burger, H. G. (2000). Inhibin and reproductive aging. Exp. Gerontol. 35, 33-39. doi: 10.1016/S0531-5565(99)00091-1
12. Burger, H. G., Dudley, E., Mamers, P., Groome, N., and Robertson, D. M. (2000). Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol. Climacteric 3, 17-24. doi: 10.3109/13697130009167595
13. Bussani, C., Papi, L., Sestini, R., Baldinotti, F., Bucciantini, S., Bruni, V., et al. (2004). Premature ovarian failure and fragile X premutation: a study on 45 women. Eur. J. Obstet. Gynecol. Reprod. Biol. 112, 189-191. doi: 10.1016/j.ejogrb.2003.06.003
14. Choe, S. A., Kim, K. C., Lee, J. Y., Kim, C. H., Hwang, D., and Jee, B. C. (2013). The relationship between the number of CGG repeats and serum level of anti-Mullerian hormone in women without FMR1 premutation. Eur. J. Obstet. Gynecol. Reprod. Biol. 169, 275-278. doi: 10.1016/j.ejogrb.2013.05.002
15. Coulam, C. B., Adamson, S. C., and Annegars, J. F. (1986). Incidence of premature ovarian failure. Obstet. Gynecol. 67, 604-606.
16. Cronister, A., Teicher, J., Rohlfs, E. M., Donnenfeld, A., and Hallam, S. (2008). Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet. Gynecol. 111, 596-601. doi: 10.1097/AOG.0b013e318163be0b
17. De Geyter, C., M'Rabet, N., De Geyter, J., Zurcher, S., Moffat, R., Bosch, N., et al. (2013). Similar prevalence of expanded CGG repeat lengths in the fragile X mental retardation I gene among infertile women and among women with proven fertility: a prospective study. Genet. Med. doi: 10.1038/gim.2013.146
18. De Vos, M., Devroey, P., and Fauser, B. C. (2010). Primary ovarian insufficiency. Lancet 376, 911-921. doi: 10.1016/S0140-6736(10)60355-8
19. Fernandez-Carvajal, I., Lopez Posadas, B., Pan, R., Raske, C., Hagerman, P. J., and Tassone, F. (2009). Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J. Mol. Diagn. 11, 306-310. doi: 10.2353/jmoldx.2009.080174
20. Finucane, B., Abrams, L., Cronister, A., Archibald, A., Bennett, R., and McConkie-Rosell, A. (2012). Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. J. Genet. Couns. 21, 752-760. doi: 10.1007/s10897-012-9524-8
21. Fisch, G. S., Snow, K., Thibodeau, S. N., Chalifaux, M., Holden, J. J., Nelson, D. L., et al. (1995). The fragile X premutation in carriers and its effect on mutation size in offspring. Am. J. Hum. Genet. 56, 1147-1155.
22. Fritz, M. A., and Speroff, L. (2011a). "Assisted reproductive technologies," in Clinical Gynecologic Endocrinology and Infertility, 8th Edn. (Philadelphia, PA: Wolters Kluwer Health; Lippincott Williams & Wilkins), 1336-1340.
23. Fritz, M. A., and Speroff, L. (2011b). "Amenorrhea," in Clinical Gynecologic Endocrinology and Infertility, 8th Edn. (Philadelphia, PA: Wolters Kluwer Health; Lippincott Williams & Wilkins), 463-473.
24. Gleicher, N., Weghofer, A., Oktay, K., and Barad, D. (2009a). Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod. Biomed. Online 19, 385-390. doi: 10.1016/S1472-6483(10)60173-3
25. Gleicher, N., Weghofer, A., Oktay, K., and Barad, D. H. (2009b). Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? Acta Obstet. Gynecol. Scand. 88, 1024-1030. doi: 10.1080/00016340903171058
26. Goldenberg, R. L., Grodin, J. M., Rodbard, D., and Ross, G. T. (1973). Gonadotropins in women with amenorrhea. The use of plasma follicle-stimulating hormone to differentiate women with and without ovarian follicles. Am. J. Obstet. Gynecol. 116, 1003-1012.
27. Hansen, K. R., Hodnett, G. M., Knowlton, N., and Craig, L. B. (2011). Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil. Steril. 95, 170-175. doi: 10.1016/j.fertnstert.2010.04.006
28. Hayashi, H., and Sayama, M. (2009). Emotional processes during pregnancy among women successfully conceived via assisted reproductive technology [Japanese]. J. Japan Acad. Midwifery 23, 83-92. doi: 10.3418/jjam.23.83
29. Hoffman, G. E., Le, W. W., Entezam, A., Otsuka, N., Tong, Z. B., Nelson, L., et al. (2012). Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency. J. Histochem. Cytochem. 60, 439-456. doi: 10.1369/0022155412441002
30. Howard, H. C., Swinnen, E., Douw, K., Vondeling, H., Cassiman, J. J., Cambon-Thomsen, A., et al. (2013). The ethical introduction of genome-based information and technologies into public health. Public Health Genomics 16, 100-109. doi: 10.1159/000346474
31. Hundscheid, R. D., Braat, D. D., Kiemeney, L. A., Smits, A. P., and Thomas, C. M. (2001). Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives. Hum. Reprod. 16, 457-462. doi: 10.1093/humrep/16.3.457
32. Jameson, J., and DeGroot, L. (2010). "Amenorrhea, anovulation, and dysfunctional uterine bleeding," in Endocrinology: Adult and Pediatric, 6th Edn., Vol. 2, eds L. J. DeGroot, J. L. Jameson, D. M. De Kretser, A. Grossman, J. C. Marshall, S. Melmed, J. T. Potts, and G. C. Weir (Philadelphia, PA: Saunders/Elsevier), 2347-2350.
33. Karimov, C. B., Moragianni, V. A., Cronister, A., Srouji, S., Petrozza, J., Racowsky, C., et al. (2011). Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum. Reprod. 26, 2077-2083. doi: 10.1093/humrep/der168
34. Klein, N. A., Battaglia, D. E., Woodruff, T. K., Padmanabhan, V., Giudice, L. C., Bremner, W. J., et al. (2000). Ovarian follicular concentrations of activin, follistatin, inhibin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-2 (IGFBP-2), IGFBP-3, and vascular endothelial growth factor in spontaneous menstrual cycles of normal women of advanced reproductive age. J. Clin. Endocrinol. Metab. 85, 4520-4525. doi: 10.1210/jcem.85.12.7056
35. Kline, J., Kinney, A., Kelly, A., Reuss, M. L., and Levin, B. (2005). Predictors of antral follicle count during the reproductive years. Hum. Reprod. 20, 2179-2189. doi: 10.1093/humrep/dei048
36. Kline, J. K., Kinney, A. M., Levin, B., Brown, S. A., Hadd, A. G., and Warburton, D. (2014). Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause 21, 740-748. doi: 10.1097/GME.0000000000000139
37. Kronquist, K. E., Sherman, S. L., and Spector, E. B. (2008). Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines. Genet. Med. 10, 845-847. doi: 10.1097/GIM.0b013e31818c2606
38. Lu, C., Lin, L., Tan, H., Wu, H., Sherman, S. L., Gao, F., et al. (2012). Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum. Mol. Genet. 21, 5039-5047. doi: 10.1093/hmg/dds348
39. Maddalena, A., Richards, C. S., McGinniss, M. J., Brothman, A., Desnick, R. J., Grier, R. E., et al. (2001). Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet. Med. 3, 200-205. doi: 10.1097/00125817-200105000-00010
40. Marozzi, A., Vegetti, W., Manfredini, E., Tibiletti, M. G., Testa, G., Crosignani, P. G., et al. (2000). Association between idiopathic premature ovarian failure and fragile X premutation. Hum. Reprod. 15, 197-202. doi: 10.1093/humrep/15.1.197
41. McConkie-Rosell, A., Abrams, L., Finucane, B., Cronister, A., Gane, L. W., Coffey, S. M., et al. (2007). Recommendations from Multi-disciplinary Focus Groups on Cascade Testing and Genetic Counseling for Fragile X-associated Disorders. J. Genetic. Couns. 16, 593-606. doi: 10.1007/s10897-007-9099-y
42. McConkie-Rosell, A., Finucane, B., Cronister, A., Abrams, L., Bennett, R. L., and Pettersen, B. J. (2005). Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J. Genetic. Couns. 14, 249-270. doi: 10.1007/s10897-005-4802-x
43. McLaughlin, M., Patrizio, P., Kayisli, U., Luk, J., Thomson, T. C., Anderson, R. A., et al. (2011). mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro. Fertil. Steril. 96, 1154.e1-1159.e1. doi: 10.1016/j.fertnstert.2011.08.040
44. Monaghan, K. G., Lyon, E., and Spector, E. B. (2013). ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. Genet. Med. 15, 575-586. doi: 10.1038/gim.2013.61
45. Murray, A., Ennis, S., MacSwiney, F., Webb, J., and Morton, N. E. (2000). Reproductive and menstrual history of females with fragile X expansions. Eur. J. Hum. Genet. 8, 247-252. doi: 10.1038/sj.ejhg.5200451
46. Murray, A., Schoemaker, M. J., Bennett, C. E., Ennis, S., Macpherson, J. N., Jones, M., et al. (2014). Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Genet. Med. 16, 19-24. doi: 10.1038/gim.2013.64
47. Murray, A., Webb, J., MacSwiney, F., Shipley, E. L., Morton, N. E., and Conway, G. S. (1999). Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women. Hum. Reprod. 14, 1217-1218. doi: 10.1093/humrep/14.5.1217
48. Nelson, L. M., Anasti, J. N., Kimzey, L. M., Defensor, R. A., Lipetz, K. J., White, B. J., et al. (1994). Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J. Clin. Endocrinol. Metab. 79, 1470-1475.
49. Nelson, S. M., and La Marca, A. (2011). The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod. Biomed. Online 23, 411-420. doi: 10.1016/j.rbmo.2011.06.011
50. Nolin, S. L., Brown, W. T., Glicksman, A., Houck, G. E. Jr., Gargano, A. D., Sullivan, A., et al. (2003). Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am. J. Hum. Genet. 72, 454-464. doi: 10.1086/367713
51. Nolin, S. L., Glicksman, A., Ding, X., Ersalesi, N., Brown, W. T., Sherman, S. L., et al. (2011). Fragile X analysis of 1112 prenatal samples from 1991 to 2010. Prenat. Diagn. 31, 925-931. doi: 10.1002/pd.2815
52. Nolin, S. L., Lewis, F. A. 3rd., Ye, L. L., Houck, G. E. Jr., Glicksman, A. E., Limprasert, P., et al. (1996). Familial transmission of the FMR1 CGG repeat. Am. J. Hum. Genet. 59, 1252-1261.
53. Nolin, S. L., Sah, S., Glicksman, A., Sherman, S. L., Allen, E., Berry-Kravis, E., et al. (2013). Fragile X AGG analysis provides new risk predictions for 45-69 repeat alleles. Am. J. Med. Genet. A 161, 771-778. doi: 10.1002/ajmg.a.35833
54. Oostra, B. A., and Willemsen, R. (2003). A fragile balance: FMR1 expression levels. Hum. Mol. Genet. 12, R249-R257. doi: 10.1093/hmg/ddg298
55. Otsuka, S., Sakamoto, Y., Siomi, H., Itakura, M., Yamamoto, K., Matumoto, H., et al. (2010). Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain Dev. 32, 110-114. doi: 10.1016/j.braindev.2008.12.015
56. Pastore, L. M., Antero, M. F., Ventura, K. A., Penberthy, J. K., Thomas, S. A., and Karns, L. B. (2014c). Attitudes towards potentially carrying the FMR1 premutation: before vs after testing of non-carrier females with occult primary ovarian insufficiency (POI). J. Genet. Couns. doi: 10.1007/s10897-014-9717-4. [Epub ahead of print].
57. Pastore, L. M., Karns, L. B., Ventura, K., Clark, M. L., Steeves, R. H., and Callanan, N. P. (2014b). Longitudinal interviews of couples diagnosed with diminished ovarian reserve undergoing Fragile X Premutation testing. J. Genet. Couns. 23, 97-107. doi: 10.1007/s10897-013-9616-0
58. Pastore, L. M., McMurry, T. L., Williams, C. D., Baker, V. B., and Young, S. L. (2014a). AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level. J. Assist. Repro. Genet. doi: 10.1016/j.fertnstert.2013.07.1519
59. Pastore, L. M., Morris, W. L., Karns, L. B., Pastore, L. M., Morris, W. L., and Karns, L. B. (2008). Emotional reaction to fragile X premutation carrier tests among infertile women. J. Genet. Couns. 17, 84-91. doi: 10.1007/s10897-007-9129-9
60. Pastore, L. M., Young, S. L., Baker, V. L., Karns, L. B., Williams, C. D., and Silverman, L. M. (2012). Elevated prevalence of 35-44 FMR1 trinucleotide repeats in women with diminished ovarian reserve. Reprod. Sci. 19, 1226-1231. doi: 10.1177/1933719112446074
61. Rebar, R. W., and Connolly, H. V. (1990). Clinical features of young women with hypergonadotropic amenorrhea. Fertil. Steril. 53, 804-810.
62. Reyniers, E., Vits, L., De Boulle, K., Van Roy, B., Van Velzen, D., de Graaff, E., et al. (1993). The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm. Nat. Genet. 4, 143-146. doi: 10.1038/ng0693-143
63. Rohr, J., Allen, E. G., Charen, K., Giles, J., He, W., Dominguez, C., et al. (2008). Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum. Reprod. 23, 1220-1225. doi: 10.1093/humrep/den050
64. Seltzer, M. M., Abbeduto, L., Greenberg, J. S., Almeida, D., Hong, J., and Witt, W. (2009). Biomarkers in the study of families of individuals with developmental disabilities. Int. Rev. Res. Ment. Retard. 37, 213-249. doi: 10.1016/S0074-7750(09)37007-X
65. Sherman, S., Pletcher, B. A., and Driscoll, D. A. (2005). Fragile X syndrome: diagnostic and carrier testing. Genet. Med. 7, 584-587. doi: 10.1097/01.GIM.0000182468.22666.dd
66. Spath, M. A., Feuth, T. B., Allen, E. G., Smits, A. P., Yntema, H. G., van Kessel, A. G., et al. (2011). Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Hum. Reprod. 26, 2185-2191. doi: 10.1093/humrep/der146
67. Streuli, I., Fraisse, T., Ibecheole, V., Moix, I., Morris, M. A., and de Ziegler, D. (2009). Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency. Fertil. Steril. 92, 464-470. doi: 10.1016/j.fertnstert.2008.07.007
68. Sullivan, A. K., Marcus, M., Epstein, M. P., Allen, E. G., Anido, A. E., Paquin, J. J., et al. (2005). Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 20, 402-412. doi: 10.1093/humrep/deh635
69. van Rooij, I., Broekmans, F. J., Scheffer, G. J., Looman, C. W., Habbema, J. D., de Jong, F. H., et al. (2005). Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil. Steril. 83, 979-987. doi: 10.1016/j.fertnstert.2004.11.029
70. Visser, J. A., and Themmen, A. P. (2005). Anti-Mullerian hormone and folliculogenesis. Mol. Cell. Endocrinol. 234, 81-86. doi: 10.1016/j.mce.2004.09.008
71. Vits, L., De Boulle, K., Reyniers, E., Handig, I., Darby, J. K., Oostra, B., et al. (1994). Apparent regression of the CGG repeat in FMR1 to an allele of normal size. Hum. Genet. 94, 523-526. doi: 10.1007/BF00211019
72. Weenen, C., Laven, J. S., Von Bergh, A. R., Cranfield, M., Groome, N. P., Visser, J. A., et al. (2004). Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol. Hum. Reprod. 10, 77-83. doi: 10.1093/molehr/gah015
73. Welt, C. K. (2008). Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin. Endocrinol. (Oxf.) 68, 499-509. doi: 10.1111/j.1365-2265.2007.03073.x
74. Welt, C. K., Smith, P. C., and Taylor, A. E. (2004). Evidence of early ovarian aging in Fragile X Premutation carriers. J. Clin. Endocrinol. Metab. 89, 4569-4574. doi: 10.1210/jc.2004-0347
75. Wittenberger, M. D., Hagerman, R. J., Sherman, S. L., McConkie-Rosell, A., Welt, C. K., Rebar, R. W., et al. (2007). The FMR1 premutation and reproduction. Fertil. Steril. 87, 456-465. doi: 10.1016/j.fertnstert.2006.09.004
76. Yu, J., Yaba, A., Kasiman, C., Thomson, T., and Johnson, J. (2011). mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS ONE 6:e21415. doi: 10.1371/journal.pone.0021415
77. Zeesman, S., Zwaigenbaum, L., Whelan, D. T., Hagerman, R. J., Tassone, F., and Taylor, S. A. M. (2004). Paternal transmission of fragile X syndrome. Am. J. Med. Genet. A 129A, 184-189. doi: 10.1002/ajmg.a.30191